GlassScriptPhysician profile
Amy Salley
NPI 1992456701
$1,929.92
in general payments reported to CMS, 2019-2025
16 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $409 · 2024: $1,413 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,929.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $399.36 | 2023-2025 | Ingrezza |
| Abbvie INC. | $279.10 | 2023-2025 | |
| Alkermes, INC. | $239.12 | 2024 | Lybalvi, Aristada, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $232.85 | 2023-2024 | Rexulti, Abilify Mycite |
| Teva Pharmaceuticals USA, INC. | $174.35 | 2024 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $131.28 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $111.23 | 2024 | Invega Sustenna |
| Corium, LLC | $107.10 | 2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $64.92 | 2024-2025 | Qelbree |
| Lundbeck LLC | $59.81 | 2023-2024 | Rexulti |
| Indivior INC. | $30.90 | 2024 | Sublocade |
| Tempus Ai, INC | $23.93 | 2024 | |
| Axsome Therapeutics, INC. | $23.58 | 2023 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $18.00 | 2025 | Cobenfy |
| Almatica Pharma LLC | $17.96 | 2024 | Loreev Xr |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $16.43 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Salley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.